Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

John Mascarenhas, MD, Heidi E. Kosiorek, MS, Lilian Varricchio, PhD, Rupali Bhave, MD, Andrew T. Kuykendall, MD, Rami Komrokji, MD, Aaron T. Gerds, MDMS, Jeanne M. Palmer, MD, Amelia R. Gabler, Lonette Sandy, Anna Rita Migliaccio, PhD, Mohamed E Salama, MD, Rona Singer Weinberg, PhD, Maureen O'Connor-McCourt, PhD, Gilles Tremblay, PhD, Paul I. Nadler, MD, Amylou C. Dueck, PhD, Ruben A. Mesa, MD FACP, Ronald Hoffman, MD

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-140830

Published: 2020

Journal Articles

Analysis of Free-Text Responses in an International Myeloproliferative Neoplasms Patient Survey to Assess Impact of the COVID-19 Pandemic on Clinical Care

Blake T. Langlais, MS, Carolyn Mead-Harvey, MS, Heidi E. Kosiorek, MS, Gina L. Mazza, PhD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Amylou C. Dueck, PhD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-143172

Published: 2020

Journal Articles

Ropeginterferon Demonstrates Safety and Efficacy in Myelofibrosis: Pilot Study Results

Jeanne M. Palmer, MD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, John Camoriano, MD, Craig Zimmerman, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-138934

Published: 2020

Journal Articles

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140853

Published: 2020

Journal Articles

Inhibition of P-Selectin Rescues the Phenotype of a Novel Genetic Animal Model for Idiopathic Pulmonary Fibrosis

Francesca Gobbo, Paola Verachi, Barbara Bacci, PhD, Maria Zingariello, PhD, Angelo Peli, PhD, Carolyn Mead-Harvey, MS, Amylou C. Dueck, PhD, Giuseppe Sarli, PhD, Anna Rita Migliaccio, PhD

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-133898

Published: 2020

Journal Articles

Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials

Gina L. Mazza, PhD, Carolyn Mead-Harvey, MS, John Mascarenhas, MD, Abdulraheem Yacoub, MD, Ronald Hoffman, MD, Heidi E. Kosiorek, MS, Josef T. Prchal, MD, Richard T. Silver, MD, Tiziano Barbui, MD, Amylou C. Dueck, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-142817

Published: 2020

Journal Articles

Financial Toxicity and Impact on Health-Related Quality of Life in Patients with Plasma Cell Disorders

Rahma M Warsame, MD, Angela Dispenzieri, MD, Amylou C. Dueck, PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140826

Published: 2020

Journal Articles

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138953

Published: 2020

Journal Articles

Clinical Trial Design Features of Myelofibrosis Trials during the Last Decade: Comprehensive Review of Clinicaltrials.Gov Data 2010-2019

Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, John Mascarenhas, MD, Ruben A. Mesa, MD FACP, Ronald Hoffman, MD, Blake T. Langlais, MS

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-137809

Published: 2020

Journal Articles

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)

Blake T. Langlais, MS, Heidi E. Kosiorek, MS, Gina L. Mazza, PhD, Carolyn Mead-Harvey, MS, Richard Butterfield, III, Jeanne M. Palmer, MD, Ruben Mesa, MD, Amylou C. Dueck, PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-142838

Published: 2020

Journal Articles

Symptom Burden in "Low Risk PV" Frequently Is Problematic and May Justify Earlier Intervention with Cytoreductive Therapy: An MPN-QOL Study Group Study

Ruben Mesa, MD, Heidi E. Kosiorek, MS, Alessandra Carobbio, BSc, Tiziano Barbui, MD, Amylou C. Dueck, PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-134583

Published: 2020

Journal Articles

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Blood (2019) 134 (Supplement_1): 2943.

https://doi.org/10.1182/blood-2019-124865

Published: 2019

Journal Articles

Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials

Andrew Dunbar, MD, Heidi E. Kosiorek, MS, Aishwarya Krishnan, Erin McGovern, BA, Young Park, BS, Minal A Patel, MPH, Rona Singer Weinberg, PhD, Abdulraheem Yacoub, MD, Amylou C. Dueck, PhD, John Mascarenhas, MD, Ross L. Levine, MD, Ronald Hoffman, MD, Raajit K. Rampal, MD PhD

Blood (2019) 134 (Supplement_1): 1661.

https://doi.org/10.1182/blood-2019-129571

Published: 2019

Journal Articles

A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms

Robyn M. Scherber, MDMPH, Martin M. Goros, MS, Jonathan Gelfond, MD PhD, Amylou C. Dueck, PhD, Sarah F Christensen, MD, Hans Hasselbalch, MD, Holly L. Geyer, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2181.

https://doi.org/10.1182/blood-2019-126803

Published: 2019

Journal Articles

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Bridget Marcellino, MD PhD, Joseph Tripodi, Michal Bar-Natan, MD, Harry Fruchtman, Noushin Farnoud, PhD, Min Lu, PhD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Vesna Najfeld, PhD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4207.

https://doi.org/10.1182/blood-2019-129565

Published: 2019

Journal Articles

Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life

Surbhi Sidana, MD, Gita Thanarajasingam, MD, Joan Griffin, PhD, Carrie A. Thompson, MD, Michelle Burtis, Rahma Warsame, MD, Jonas Paludo, MD, Andrea Cheville, Morie A Gertz, MD, Angela Dispenzieri, MD, Jose Villasboas, MD, Stephen M Ansell, MD PhD, S. Vincent Rajkumar, MD, Kathleen J Yost, PhD, N. Nora Bennani, MD, Mustaqeem Siddiqui, MD, Yi Lin, MD PhD, Shaji K. Kumar, MD, Amylou C. Dueck, PhD

Blood (2019) 134 (Supplement_1): 794.

https://doi.org/10.1182/blood-2019-121715

Published: 2019

Journal Articles

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Bridget Marcellino, MD PhD, Bruno Cassinat, PharmD, PhD, Noushin Farnoud, PhD, Min Lu, PhD, Emmanuelle Verger, PhD, Erin McGovern, BA, Minal A Patel, MPH, Heidi E. Kosiorek, MS, Meenakshi Mehrotra, PhD, Jane Houldsworth, PhD, Amylou C. Dueck, PhD, Michael Rossi, PhD, Jean-Jacques Kiladjian, MD PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 838.

https://doi.org/10.1182/blood-2019-128342

Published: 2019

Journal Articles

A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408

Fangxin Hong, PhD, Andrew M. Evens, DO, MSc, Paul J Novotny, M.S., Thomas M. Habermann, MD, Ranjana H Advani, MD, Randy D. Gascoyne, MD, Thomas E. Witzig, MD, Andrew Quon, MD, Erik A. Ranheim, MD PhD, Amylou C. Dueck, PhD, Brad S Kahl, MD, Gita Thanarajasingam, MD

Blood (2018) 132 (Supplement 1): 4157.

https://doi.org/10.1182/blood-2018-99-117249

Published: 2018

Journal Articles

Prevalence and Risk Factors for Opioid-Related Complications in Patients with Myeloproliferative Neoplasms: An International Survey of 502 Patients By the MPN Quality of Life Study Group

Holly L. Geyer, MD, Robyn M. Scherber, MD MPH, Gina Mazza, PhD, Blake Langlais, Leslie Padrnos, MD, Jeanne Palmer, MD, Amylou C. Dueck, PhD, Ruben A. Mesa, MD

Blood (2018) 132 (Supplement 1): 4297.

https://doi.org/10.1182/blood-2018-99-115143

Published: 2018

Journal Articles

Addressing the Adequacy of Current MPN Pain Management Strategies: An International Survey of 502 Patients By the MPN Quality of Life Study Group

Holly L. Geyer, MD, Robyn M. Scherber, MD MPH, Gina Mazza, PhD, Blake T. Langlais, Ruben A. Mesa, MD, Leslie Padrnos, MD, Amylou C. Dueck, PhD, Jeanne Palmer, MD

Blood (2018) 132 (Supplement 1): 4298.

https://doi.org/10.1182/blood-2018-99-115095

Published: 2018

NARROW

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

Analysis of Free-Text Responses in an International Myeloproliferative Neoplasms Patient Survey to Assess Impact of the COVID-19 Pandemic on Clinical Care

Ropeginterferon Demonstrates Safety and Efficacy in Myelofibrosis: Pilot Study Results

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)

Inhibition of P-Selectin Rescues the Phenotype of a Novel Genetic Animal Model for Idiopathic Pulmonary Fibrosis

Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials

Financial Toxicity and Impact on Health-Related Quality of Life in Patients with Plasma Cell Disorders

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Clinical Trial Design Features of Myelofibrosis Trials during the Last Decade: Comprehensive Review of Clinicaltrials.Gov Data 2010-2019

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)

Symptom Burden in "Low Risk PV" Frequently Is Problematic and May Justify Earlier Intervention with Cytoreductive Therapy: An MPN-QOL Study Group Study

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials

A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408

Prevalence and Risk Factors for Opioid-Related Complications in Patients with Myeloproliferative Neoplasms: An International Survey of 502 Patients By the MPN Quality of Life Study Group

Addressing the Adequacy of Current MPN Pain Management Strategies: An International Survey of 502 Patients By the MPN Quality of Life Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only